Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Philips, G; Halabi, S; Sanford, B; Bajorin, D; Small, E

Published Date

  • July 15, 2004

Published In

Volume / Issue

  • 22 / 14

Start / End Page

  • 391S - 391S

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Conference Location

  • New Orleans, LA

Conference Start Date

  • June 5, 2004

Conference End Date

  • June 8, 2004